

Marco Platania

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2857519/publications.pdf>

Version: 2024-02-01

48
papers

1,160
citations

430754

18
h-index

395590

33
g-index

49
all docs

49
docs citations

49
times ranked

1823
citing authors

#	ARTICLE	IF	CITATIONS
1	Knowledge, attitudes and practices towards patients with HIV/AIDS in staff nurses in one university hospital in Sicily. , 2022, 10, .		7
2	The contingent equilibrium during imbalanced volcano tourism demand through fee estimation: An empirical analysis of tourism in Mount Etna. Journal of Environmental Management, 2022, 316, 115235.	3.8	8
3	PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study. Health and Quality of Life Outcomes, 2020, 18, 252.	1.0	10
4	Recurrent thrombosis followed by Lazarus response in <i>ROS1</i> rearranged NSCLC treated with crizotinib: a case report. Tumori, 2020, 106, NP41-NP45.	0.6	3
5	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clinical Colorectal Cancer, 2020, 19, 156-164.	1.0	16
6	Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer, 2019, 138, 79-87.	0.9	29
7	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. Scientific Reports, 2019, 9, 12993.	1.6	21
8	Analysing the Mediating Effect of Heritage Between Locals and Visitors: An Exploratory Study Using Mission Patrimoine as a Case Study. Sustainability, 2019, 11, 3015.	1.6	7
9	Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis. Oncology Research and Treatment, 2019, 42, 182-189.	0.8	22
10	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer, 2019, 132, 17-23.	0.9	12
11	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. Critical Reviews in Oncology/Hematology, 2018, 123, 57-73.	2.0	41
12	Clinical implications for pro-GRP in small cell lung cancer. A single center experience. International Journal of Biological Markers, 2018, 33, 55-61.	0.7	18
13	Events and Tourism Development within a Local Community: The Case of Winchester (UK). Sustainability, 2018, 10, 3728.	1.6	24
14	Willingness to pay for protected areas: A case of Etna Park. Ecological Indicators, 2018, 93, 201-206.	2.6	29
15	“œSystemic Strategy at the Patient's Service” A Congress Report on Supportive Care in Oncology. Tumori, 2017, 103, P1-P8.	0.6	0
16	Uncommon Somatic Mutations in Metastatic NUT Midline Carcinoma. Tumori, 2017, 103, S5-S8.	0.6	10
17	Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. Current Drug Targets, 2017, 18, 341-362.	1.0	8
18	Entertainment marketing, experiential consumption and consumer behavior: the determinant of choice of wine in the store. Wine Economics and Policy, 2016, 5, 87-95.	1.3	31

#	ARTICLE	IF	CITATIONS
19	Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?. Tumori, 2016, 102, 18-30.	0.6	8
20	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 2016, 27, 417-423.	0.6	122
21	Treatment of lung large cell neuroendocrine carcinoma. Tumor Biology, 2016, 37, 7047-7057.	0.8	46
22	Hyponatremia in Cancer Patients. Tumori, 2015, 101, 246-248.	0.6	10
23	The OECI Model: The Experience of INT Milan with a Focus on the Integration of Psycho-oncology Support. Tumori, 2015, 101, S25-S32.	0.6	0
24	Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Critical Reviews in Oncology/Hematology, 2015, 94, 213-227.	2.0	51
25	Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. International Journal of Colorectal Disease, 2015, 30, 429-430.	1.0	1
26	Italian Trade Specialization: Persistence and Change in Regional Agri-Food Production. Agris on-line Papers in Economics and Informatics, 2015, 7, 101-109.	0.3	8
27	Gingival Metastasis as First Sign of Multiorgan Dissemination of Epithelioid Malignant Mesothelioma. Journal of Thoracic Oncology, 2014, 9, 1226-1229.	0.5	6
28	Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders. Cancer Treatment Reviews, 2014, 40, 197-203.	3.4	36
29	To Target or Not to Target, That Is the Question. Journal of Clinical Oncology, 2013, 31, 1254-1254.	0.8	3
30	Adattamento e competizione dei distretti industriali italiani. Archivio Di Studi Urbani E Regionali, 2013, , 107-131.	0.2	1
31	Neuroendocrine tumors of unknown primary site: Gold dust or misdiagnosed neoplasms?. Tumori, 2011, 97, 564-567.	0.6	27
32	Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Targeted Oncology, 2011, 6, 181-186.	1.7	7
33	Parents' attitudes and behaviours towards recommended vaccinations in Sicily, Italy. BMC Public Health, 2011, 11, 305.	1.2	24
34	7. False Positives and False Negatives in Neuroendocrine Tumors Diagnosis: Clinical Reports. Tumori, 2010, 96, 827-832.	0.6	1
35	An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review. Tumori, 2010, 96, 1031-1034.	0.6	1
36	Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes. Tumori, 2009, 95, 501-507.	0.6	4

#	ARTICLE	IF	CITATIONS
37	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2009, 90, 214-219.	1.2	97
38	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. <i>Oncology Reviews</i> , 2009, 3, 79-87.	0.8	3
39	Single-Institution Series of Early-Stage Merkel Cell Carcinoma: Long-Term Outcomes in 95 Patients Managed with Surgery Alone. <i>Annals of Surgical Oncology</i> , 2009, 16, 2985-2993.	0.7	50
40	Primary Uterine Cervix Melanoma Resembling Malignant Peripheral Nerve Sheath Tumor: A Case Report. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 596-600.	0.9	19
41	Prostate Adenocarcinoma Presenting with Supraclavicular Node Enlargement: Report of a Case. <i>Tumori</i> , 2008, 94, 769-771.	0.6	3
42	Pulmonary Carcinoid Tumours: Indolent but Not Benign. <i>Oncology</i> , 2007, 73, 162-168.	0.9	29
43	Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2007, 73, 204-209.	0.9	30
44	Merkel Cell Carcinoma after Liver Transplantation: A Case Report. <i>Tumori</i> , 2007, 93, 323-326.	0.6	10
45	Renal Cell Cancer and Sorafenib: Skin Toxicity and Treatment Outcome. <i>Tumori</i> , 2007, 93, 201-203.	0.6	7
46	Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 637-642.	1.1	218
47	Merkel cell carcinoma after liver transplantation: a case report. <i>Tumori</i> , 2007, 93, 323-6.	0.6	4
48	Typical products and consumer preferences: the "soppresata" case. <i>British Food Journal</i> , 2006, 108, 385-395.	1.6	38